Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(2):226–233. doi: 10.1038/bjc.1997.366

3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.

G Vaidyanathan 1, X G Zhao 1, R H Larsen 1, M R Zalutsky 1
PMCID: PMC2223928  PMID: 9231923

Abstract

An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to possess many properties similar to those of the parent compound. Moreover, 4-fluoro-3-iodobenzylguanidine (FIBG) was retained in vitro by human neuroblastoma cells to a much greater extent than MIBG itself. Since alpha-emitters such as 211At could be valuable for the treatment of micrometastatic disease, an FIBG analogue in which the iodine atom is replaced by 211At would be of interest. In this study, we have evaluated the in vitro and in vivo properties of 3-[211At]astato-4-fluorobenzylguanidine ([211At]AFBG). The specific binding of [211At]AFBG to SK-N-SH human neuroblastoma cells remained fairly constant over 2- to 3-log activity range and was similar to that of [131I]MIBG. The uptake of [211At]AFBG by this cell line was reduced by desipramine, ouabain, 4 degrees C incubation, noradrenaline, unlabelled MIBG and FIBG, suggesting that its uptake is specifically mediated through an active uptake-1 mechanism. Over the 16 h period studied, the amount of [211At]AFBG retained was similar to that of [131I]FIBG, whereas the per cent of retained meta-[211At]astatobenzylguanidine ([211At]MABG) was considerably less than that of [131I]FIBG (53% vs 75%; P < 0.05). The IC50 values for the inhibition of uptake of [131I]MIBG, [211At]MABG, [125I]FIBG and [211At]AFBG by unlabelled MIBG were 209, 300, 407 and 661 nM respectively, suggesting that the affinities of these tracers for the noradrenaline transporter in SK-N-SH cells increase in that order. Compared with [211At]MABG, higher uptake of [211At]AFBG was seen in vivo in normal mouse target tissues such as heart and, to a certain extent, in adrenals. That the uptake of [211At]AFBG in these tissues was related to the uptake-1 mechanism was demonstrated by its reduction when mice were pretreated with desipramine. However, the stability of [211At]AFBG towards in vivo dehalogenation was less than that of [211At]MABG, as evidenced by the higher uptake of 211At in thyroid, spleen, lungs and stomach.

Full text

PDF
226

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnette W. E. The synthesis and biology of fluorinated prostacyclins. CRC Crit Rev Biochem. 1984;15(3):201–235. [PubMed] [Google Scholar]
  2. Biedler J. L., Helson L., Spengler B. A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973 Nov;33(11):2643–2652. [PubMed] [Google Scholar]
  3. Buck J., Bruchelt G., Girgert R., Treuner J., Niethammer D. Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res. 1985 Dec;45(12 Pt 1):6366–6370. [PubMed] [Google Scholar]
  4. Garaventa A., Guerra P., Arrighini A., Bertolazzi L., Bestagno M., De Bernardi B., Lanino E., Villavecchia G. P., Claudiani F. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer. 1991 Feb 15;67(4):922–928. doi: 10.1002/1097-0142(19910215)67:4<922::aid-cncr2820670411>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  5. Garg P. K., Harrison C. L., Zalutsky M. R. Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment. Cancer Res. 1990 Jun 15;50(12):3514–3520. [PubMed] [Google Scholar]
  6. Gaze M. N., Wheldon T. E., O'Donoghue J. A., Hilditch T. E., McNee S. G., Simpson E., Barrett A. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer. 1995;31A(2):252–256. doi: 10.1016/0959-8049(94)e0036-4. [DOI] [PubMed] [Google Scholar]
  7. Goldman P. The carbon-fluorine bond in compounds of biological interest. Science. 1969 Jun 6;164(3884):1123–1130. doi: 10.1126/science.164.3884.1123. [DOI] [PubMed] [Google Scholar]
  8. Klingebiel T., Treuner J., Ehninger G., Keller K. D., Dopfer R., Feine U., Niethammer D. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects. Cancer Chemother Pharmacol. 1989;25(2):143–148. doi: 10.1007/BF00692356. [DOI] [PubMed] [Google Scholar]
  9. Larsen R. H., Wieland B. W., Zalutsky M. R. Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction. Appl Radiat Isot. 1996 Feb;47(2):135–143. doi: 10.1016/0969-8043(95)00285-5. [DOI] [PubMed] [Google Scholar]
  10. Mairs R. J., Angerson W. J., Babich J. W., Murray T. Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastoma. Prog Clin Biol Res. 1991;366:495–501. [PubMed] [Google Scholar]
  11. Mangner T. J., Tobes M. C., Wieland D. W., Sisson J. C., Shapiro B. Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma. J Nucl Med. 1986 Jan;27(1):37–44. [PubMed] [Google Scholar]
  12. O'Donoghue J. A., Wheldon T. E., Babich J. W., Moyes J. S., Barrett A., Meller S. T. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma. Br J Radiol. 1991 May;64(761):428–434. doi: 10.1259/0007-1285-64-761-428. [DOI] [PubMed] [Google Scholar]
  13. Servidei T., Iavarone A., Lasorella A., Mastrangelo S., Riccardi R. Release mechanisms of [125I]meta-iodobenzylguanidine in neuroblastoma cells: evidence of a carrier-mediated efflux. Eur J Cancer. 1995;31A(4):591–595. doi: 10.1016/0959-8049(95)00042-h. [DOI] [PubMed] [Google Scholar]
  14. Shapiro B., Gross M. D. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol. 1987;15(4):170–177. doi: 10.1002/mpo.2950150406. [DOI] [PubMed] [Google Scholar]
  15. Sisson J. C., Hutchinson R. J., Shapiro B., Zasadny K. R., Normolle D., Wieland D. M., Wahl R. L., Singer D. A., Mallette S. A., Mudgett E. E. Iodine-125-MIBG to treat neuroblastoma: preliminary report. J Nucl Med. 1990 Sep;31(9):1479–1485. [PubMed] [Google Scholar]
  16. Smets L. A., Loesberg C., Janssen M., Metwally E. A., Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 1989 Jun 1;49(11):2941–2944. [PubMed] [Google Scholar]
  17. Strickland D. K., Vaidyanathan G., Zalutsky M. R. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res. 1994 Oct 15;54(20):5414–5419. [PubMed] [Google Scholar]
  18. Vaidyanathan G., Affleck D. J., Zalutsky M. R. (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. J Med Chem. 1994 Oct 14;37(21):3655–3662. doi: 10.1021/jm00047a022. [DOI] [PubMed] [Google Scholar]
  19. Vaidyanathan G., Affleck D. J., Zalutsky M. R. No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine. Bioconjug Chem. 1996 Jan-Feb;7(1):102–107. doi: 10.1021/bc950078i. [DOI] [PubMed] [Google Scholar]
  20. Vaidyanathan G., Affleck D. J., Zalutsky M. R. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med. 1995 Apr;36(4):644–650. [PubMed] [Google Scholar]
  21. Vaidyanathan G., Strickland D. K., Zalutsky M. R. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent. Int J Cancer. 1994 Jun 15;57(6):908–913. doi: 10.1002/ijc.2910570622. [DOI] [PubMed] [Google Scholar]
  22. Vaidyanathan G., Zalutsky M. R. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug Chem. 1992 Nov-Dec;3(6):499–503. doi: 10.1021/bc00018a006. [DOI] [PubMed] [Google Scholar]
  23. Vaidyanathan G., Zalutsky M. R. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot. 1993 Mar;44(3):621–628. doi: 10.1016/0969-8043(93)90179-e. [DOI] [PubMed] [Google Scholar]
  24. Vaidyanathan G., Zhao X. G., Strickland D. K., Zalutsky M. R. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. J Nucl Med. 1997 Feb;38(2):330–334. [PubMed] [Google Scholar]
  25. Valette H., Loc'h C., Mardon K., Bendriem B., Merlet P., Fuseau C., Sabry S., Raffel D., Mazière B., Syrota A. Bromine-76-metabromobenzylguanidine: a PET radiotracer for mapping sympathetic nerves of the heart. J Nucl Med. 1993 Oct;34(10):1739–1744. [PubMed] [Google Scholar]
  26. Zalutsky M. R., Garg P. K., Friedman H. S., Bigner D. D. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7149–7153. doi: 10.1073/pnas.86.18.7149. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES